5
ESMO-MCBS v1.1
Scorecard version: 1
Indication details
- Tumour Type
- Genitourinary Cancers
- Tumour Sub-type
- Prostate cancer
- Tumour stage
- Metastatic
- Combined Agent(s)
- Best standard of care
- Control Arm
- Best standard of care + placebo
- Treatment Setting
- Late line and bone pain, castration-refractory, late line and bone pain
- Trial Name
- ALSYMPCA
Primary Outcome(s)
- Primary Outcome(s)
- OS
- Form(s)
- Form 2a
Outcome Data
- OS Control
- 11.3 months
- OS Gain
- 3.6 months
- OS HR
- 0.70 (0.58-0.83)
- QoL Comment
- Improved
Final Score (after adjustments)
- Preliminary non-curative score
- 4
- QoL adjustment
- 1+
- Final non-curative Score
- 5
- Release date
- 11.12.2018
ChT; chemotherapy; DFS, disease-free survival; DoR, duration of response; EFS, event-free survival; FFS, failure-free survival; HR, hazard ratio; iDFS, invasive disease-free survival; ITT, intention to treat; MFS, metastasis-free survival; ORR, overall response rate; OS, overall survival; pCR, pathologic complete response/remission; PE, point estimate; PFS, progression-free survival; QoL, quality of life; RFS, relapse-free survival; RR, response rate; SD, stable disease; SSA, somatostatin analogue; SSTR, somatostatin receptor; TKI, tyrosine kinase inhibitor, TTP, time to progression